BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15735564)

  • 1. Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients.
    Tavangar SM; Shariftabrizi A; Soroush AR
    Med Sci Monit; 2005 Mar; 11(3):CR123-6. PubMed ID: 15735564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
    Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
    Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
    Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?
    Angiero F; Sordo RD; Dessy E; Rossi E; Berenzi A; Stefani M; Sidoni A
    J Oral Pathol Med; 2008 Mar; 37(3):145-50. PubMed ID: 18251938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters.
    Essapen S; Thomas H; Green M; De Vries C; Cook MG; Marks C; Topham C; Modjtahedi H
    Int J Oncol; 2004 Feb; 24(2):241-8. PubMed ID: 14719098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients.
    Cunningham MP; Essapen S; Thomas H; Green M; Lovell DP; Topham C; Marks C; Modjtahedi H
    Int J Oncol; 2006 Feb; 28(2):329-35. PubMed ID: 16391786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
    Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
    J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
    Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
    Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer.
    Xia WY; Lien HC; Wang SC; Pan Y; Sahin A; Kuo YH; Chang KJ; Zhou X; Wang H; Yu Z; Hortobagyi G; Shi DR; Hung MC
    Breast Cancer Res Treat; 2006 Aug; 98(3):295-301. PubMed ID: 16752078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.